ClinicalTrials.Veeva

Menu

Injectable Lidocaine Versus Lidocaine/Tetracaine Patch for the Incision and Drainage of Skin Abscesses

U

University of North Carolina System

Status and phase

Completed
Early Phase 1

Conditions

Cutaneous Abscess
Pain

Treatments

Drug: Lidocaine/tetracaine patch
Drug: 1% lidocaine

Study type

Interventional

Funder types

Other

Identifiers

NCT02066818
ECUEM-Synera

Details and patient eligibility

About

Local anesthesia used for incision and drainage of abscesses is known to be painful.

We studied the analgesia provided by a lidocaine/tetracaine patch compared to injectable lidocaine during incision and drainage (I&D) of skin abscesses.

Local injection of lidocaine provided similar analgesia compared to the lidocaine/tetracaine patch during I&D of skin abscesses in the Emergency Department. Pain at presentation and following the procedure was similar in both groups.

Enrollment

20 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age>18 years
  • Skin abscess in need of incision and drainage (judged by treating physician)

Exclusion criteria

  • Allergy to lidocaine or tetracaine
  • Non-intact skin
  • Unable/unwilling to provide informed consent

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

20 participants in 2 patient groups

Lidocaine Injection
Active Comparator group
Description:
Incision and drainage performed after patient received placebo patch with injection of 1% lidocaine into the site of the abscess.
Treatment:
Drug: 1% lidocaine
Lidocaine/tetracaine patch
Experimental group
Description:
Incision and drainage performed after patient received active lidocaine/tetracaine patch and injection of 10cc of saline into site of abscess
Treatment:
Drug: Lidocaine/tetracaine patch

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems